Study DMD114044: A phase III, randomized, double blind, placebo-controlled clinical study to assess the efficacy and safety of GSK2402968 in subjects with Duchenne muscular dystrophy
The study is expected to complete in July 2013, with study results expected in late 2013. The results will be presented at the first appropriate medical conference. Note that GSK2402968 will be referred to by its generic name ‘drisapersen’ in future communications.
John E. Kraus, MD, PhD Padraig Wright, MD, PhD